Published in Internist (Berl) on August 23, 2017
A controlled trial of renal denervation for resistant hypertension. N Engl J Med (2014) 14.22
Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol (2011) 3.08
Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens (2013) 2.69
Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension (2010) 2.38
Early sympathetic activation in the initial clinical stages of chronic renal failure. Hypertension (2011) 2.32
Influence of prolonged baroreflex activation on arterial pressure in angiotensin hypertension. Hypertension (2005) 2.23
Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction. JACC Heart Fail (2015) 2.12
Prolonged activation of the baroreflex produces sustained hypotension. Hypertension (2004) 1.86
Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol (2010) 1.82
Effect of cardiac sympathetic nervous activity on mode of death in congestive heart failure. Eur Heart J (2001) 1.75
Prolonged activation of the baroreflex abolishes obesity-induced hypertension. Hypertension (2007) 1.48
Effects of chronic baroreceptor stimulation on the autonomic cardiovascular regulation in patients with drug-resistant arterial hypertension. Hypertension (2009) 1.33
Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. J Am Soc Hypertens (2012) 1.20
Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens (2012) 1.19
An implantable carotid sinus baroreflex activating system: surgical technique and short-term outcome from a multi-center feasibility trial for the treatment of resistant hypertension. Eur J Vasc Endovasc Surg (2007) 1.02
Global- and renal-specific sympathoinhibition in aldosterone hypertension. Hypertension (2015) 0.96
Impact of baroreflex activation therapy on renal function--a pilot study. Am J Nephrol (2014) 0.89
An implantable carotid sinus stimulator for drug-resistant hypertension: surgical technique and short-term outcome from the multicenter phase II Rheos feasibility trial. J Vasc Surg (2006) 0.89
Heterogeneity of autonomic regulation in hypertension and neurovascular contact. J Hypertens (2002) 0.89
Renal responses to long-term carotid baroreflex activation therapy in patients with drug-resistant hypertension. Hypertension (2013) 0.87
Baroreflex activation for the treatment of hypertension: principles and practice. Expert Rev Med Devices (2006) 0.82
Acute Response to Unilateral Unipolar Electrical Carotid Sinus Stimulation in Patients With Resistant Arterial Hypertension. Hypertension (2016) 0.81
Role of Chemoreceptor Activation in Hemodynamic Responses to Electrical Stimulation of the Carotid Sinus in Conscious Rats. Hypertension (2015) 0.80
Limited acute influences of electrical baroreceptor activation on insulin sensitivity and glucose delivery: a randomized, double-blind, crossover clinical study. Diabetes (2014) 0.80
Effects of Baroreflex Activation Therapy on Ambulatory Blood Pressure in Patients With Resistant Hypertension. Hypertension (2016) 0.80
Baroreflex activation therapy lowers arterial pressure without apparent stimulation of the carotid bodies. Hypertension (2015) 0.79
Effects of baroreflex activation therapy on arterial stiffness and central hemodynamics in patients with resistant hypertension. J Hypertens (2015) 0.78
An exploratory propensity score matched comparison of second-generation and first-generation baroreflex activation therapy systems. J Am Soc Hypertens (2016) 0.77
Acute on/off effects and chronic blood pressure reduction after long-term baroreflex activation therapy in resistant hypertension. J Hypertens (2015) 0.77
Unrecognized secondary causes of hypertension in patients with hypertensive urgency/emergency: prevalence and co-prevalence. Clin Res Cardiol (2010) 0.77
Long-term effects of baroreflex activation therapy on glucose metabolism. Acta Diabetol (2014) 0.77
Sustained Reduction of Blood Pressure With Baroreceptor Activation Therapy: Results of the 6-Year Open Follow-Up. Hypertension (2017) 0.77
Blood pressure after blinded, randomized withdrawal, and resumption of baroreceptor-activating therapy. J Hypertens (2017) 0.77
Baroreflex Activation Therapy in Heart Failure With Reduced Ejection Fraction: Available Data and Future Perspective. Curr Heart Fail Rep (2016) 0.77
Unilateral baroreceptor activation therapy: the beauty of asymmetry. Expert Rev Cardiovasc Ther (2015) 0.77
Baroreflex activation therapy in patients with end-stage renal failure: proof of concept. J Hypertens (2015) 0.76
Baroreflex activation therapy in patients with prior renal denervation. J Hypertens (2016) 0.76
Prolonged Baroreflex Activation Abolishes Salt-Induced Hypertension After Reductions in Kidney Mass. Hypertension (2016) 0.75